ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AZN Astrazeneca Plc

10,732.00
-10.00 (-0.09%)
Last Updated: 13:39:25
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -10.00 -0.09% 10,732.00 10,730.00 10,734.00 10,780.00 10,700.00 10,756.00 359,457 13:39:25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 27.86 165.93B

AstraZeneca PLC Director/PDMR Shareholding (6358A)

27/03/2017 3:00pm

UK Regulatory


Astrazeneca (LSE:AZN)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Astrazeneca Charts.

TIDMAZN

RNS Number : 6358A

AstraZeneca PLC

27 March 2017

27 March 2017 15:00 BST

TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

AstraZeneca PLC (the Company) announces that, on 24 March 2017, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were each granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) or of American Depositary Shares (ADSs) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below. Two ADSs are equivalent to one Ordinary Share.

 
 PDMR            Ordinary     ADSs awarded   Ordinary     ADSs awarded   Award 
                  Shares       under          Shares       under          price 
                  awarded      the AZDBP      awarded      the AZPSP      per Ordinary 
                  under                       under                       Share 
                  the AZDBP                   the AZPSP                   / per 
                                                                          ADS 
--------------  -----------  -------------  -----------  -------------  -------------- 
 Pascal 
  Soriot              7,968                     125,009                       GBP48.80 
--------------  -----------  -------------  -----------  -------------  -------------- 
 Marc Dunoyer         4,262                      59,439                       GBP48.80 
--------------  -----------  -------------  -----------  -------------  -------------- 
 Sean Bohen                          3,452                      97,507          $30.88 
--------------  -----------  -------------  -----------  -------------  -------------- 
 Mark Mallon                         2,503                      82,190          $30.88 
--------------  -----------  -------------  -----------  -------------  -------------- 
 

The AZDBP award represents the portion of each PDMR's annual bonus for 2016 that they are required to defer into shares. The Ordinary Shares and ADSs awarded under the AZDBP are subject to a three-year holding period (24 March 2017 to 23 March 2020).

The AZPSP award is subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year performance period (1 January 2017 to 31 December 2019). The AZPSP award will vest on the third anniversary of the date of grant, other than the awards granted to the Executive Directors, Mr Soriot and Mr Dunoyer, which will be subject to a further two-year holding period before vesting.

Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2016, which is available on the Company's website at www.astrazeneca.com/annualreport2016.

The Company also announces that, on 24 March 2017, Mr Bohen was granted an award of 48,753 ADSs under the terms of the AstraZeneca Restricted Share Plan (AZRSP) at an award price of $30.88 per ADS. The ADSs awarded under the AZRSP are subject to continued employment and will vest on the third anniversary of the date of grant.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 
 Media Enquiries 
 Esra Erkal-Paler       UK/Global                                 +44 203 749 5638 
 Vanessa Rhodes         UK/Global                                 +44 203 749 5736 
 Karen Birmingham       UK/Global                                 +44 203 749 5634 
 Rob Skelding           UK/Global                                 +44 203 749 5821 
 Jacob Lund             Sweden                                    +46 8 553 260 20 
 Michele Meixell        US                                        +1 302 885 2677 
 Investor Relations 
 Thomas Kudsk Larsen                                              +44 203 749 5712 
 Craig Marks            Finance, Fixed Income, M&A                +44 7881 615 764 
 Henry Wheeler          Oncology                                  +44 203 749 5797 
 Mitchell Chan          Oncology                                  +1 240 477 3771 
 Lindsey Trickett       Cardiovascular & Metabolic Diseases       +1 240 543 7970 
 Nick Stone             Respiratory                               +44 203 749 5716 
 Christer Gruvris       Autoimmunity, Neuroscience & Infection    +44 203 749 5711 
 US toll free                                                     +1 866 381 7277 
 

Adrian Kemp

Company Secretary, AstraZeneca PLC

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUBVURBRAOUAR

(END) Dow Jones Newswires

March 27, 2017 10:00 ET (14:00 GMT)

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart

Your Recent History

Delayed Upgrade Clock